A Phase Ib/II Study of Oprozomib in Patients with Advanced Multiple Myeloma and Waldenström Macroglobulinemia.
Journal
Clinical cancer research : an official journal of the American Association for Cancer Research
ISSN: 1557-3265
Titre abrégé: Clin Cancer Res
Pays: United States
ID NLM: 9502500
Informations de publication
Date de publication:
15 08 2019
15 08 2019
Historique:
received:
27
11
2018
revised:
07
02
2019
accepted:
14
05
2019
pubmed:
31
5
2019
medline:
20
8
2020
entrez:
31
5
2019
Statut:
ppublish
Résumé
The oral proteasome inhibitor oprozomib has shown preclinical antitumor activity. Here, we report phase Ib/II study results investigating single-agent oprozomib in patients with relapsed multiple myeloma and Waldenström macroglobulinemia. The primary objectives were to determine the MTD, safety, and tolerability of oprozomib (phase Ib) as well as overall response rate (ORR; phase II). Oprozomib was administered once daily on days 1, 2, 8, and 9 (2/7 schedule) or days 1 to 5 (5/14 schedule) of a 14-day cycle. In patients with multiple myeloma or Waldenström macroglobulinemia ( This study demonstrated promising efficacy of single-agent oprozomib in patients with relapsed multiple myeloma and Waldenström macroglobulinemia.
Identifiants
pubmed: 31142508
pii: 1078-0432.CCR-18-3728
doi: 10.1158/1078-0432.CCR-18-3728
doi:
Substances chimiques
ONX 0912
0
Oligopeptides
0
Proteasome Inhibitors
0
Types de publication
Clinical Trial, Phase I
Clinical Trial, Phase II
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
4907-4916Informations de copyright
©2019 American Association for Cancer Research.